Differentiation Antigens

Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.

Also Known As:

Networked: 1051 relevant articles (5 outcomes, 75 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rosenberg, Steven A: 7 articles (02/2015 - 05/2002)
2.	Houghton, Alan N: 7 articles (11/2007 - 04/2004)
3.	Luiten, Rosalie M: 6 articles (11/2014 - 12/2005)
4.	Jungbluth, Achim A: 6 articles (03/2013 - 10/2002)
5.	Wolchok, Jedd D: 6 articles (11/2007 - 04/2004)
6.	Marincola, Francesco M: 5 articles (05/2014 - 05/2002)
7.	Wunderlich, John R: 4 articles (02/2015 - 05/2002)
8.	Busam, Klaus J: 4 articles (06/2014 - 10/2002)
9.	Li, Y: 4 articles (01/2012 - 02/2000)
10.	Anichini, Andrea: 4 articles (12/2011 - 10/2002)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2010 - "Our studies uncover the cells at the origin of BCC in mice and demonstrate that expression of differentiation markers in tumour cells is not necessarily predictive of the cancer initiating cells." 11/01/1998 - "In the study presented here, we examined the expression pattern of several differentiation markers and observed that p53m tumors exhibited a less differentiated phenotype than tumors elicited in non-transgenic mice. " 04/15/2015 - "Loxl2 levels in premalignant tumors negatively correlate with expression of epidermal differentiation markers and components of the Notch1 pathway. " 09/01/2014 - "Primary cultures demonstrated good correlation for differentiation markers compared to parent cancers, and were highly dynamic in 3D culture. " 04/01/2014 - "Cells from sphere-forming cultures displayed a robust self-renewal capacity and exhibited genotypic, phenotypic, and functional properties consistent with each of the three molecular subtypes seen in primary tumors, including expression of endothelial progenitor cell (CD133 and CD34) and endothelial cell (CD105, CD146, and αvβ3 integrin) markers, expression of early hematopoietic (CD133, CD117, and CD34) and myeloid (CD115 and CD14) differentiation markers in parallel with increased phagocytic capacity, and acquisition of adipogenic potential. "
2.	Lymphoma (Lymphomas) 10/01/2008 - "The differentiation antigens, GCB versus non-GCB phenotype, or lymphoma-associated translocations were of no prognostic significance. " 01/01/2008 - "However, the value of B-cell differentiation markers in primary central nervous system lymphoma (PCNSL) is less clear. " 01/01/2000 - "The revised European-American lymphoma classification (REAL) uses histology, clusters of differentiation markers, histochemistry, and cytogenetics for definitive identification. " 04/22/1993 - "The neoplastic cells of both these LMs also showed common immunophenotypic features such as frequent absence of B- and T-cell differentiation markers and expression of the Ki-I activation marker, while SNCC and LCI lymphomas were mainly of mature B-cell origin and Ki-I-. " 09/01/1992 - "The lymphomas resembled spontaneous AKR/J thymic lymphomas in their expression of lymphoid differentiation antigens, and they may represent sequential stages in the differentiation of immature T lymphocytes. "
3.	B-Cell Lymphoma (Lymphoma, B Cell) 07/01/2014 - "PBL is distinguished from other B-cell lymphomas by the presence of plasmacytic differentiation markers such as CD38, CD138, and MUM1. " 02/01/1991 - "In order to compare primary gastro-intestinal (GI) B-cell lymphomas histomorphologically and immunophenotypically with orthologous steps of B-cell differentiation within the mucosa-associated lymphoid tissue (MALT) of the GI tract, a comprehensive panel of well characterized leucocyte differentiation antigens was composed. " 07/01/2011 - "Flow cytometry was used to identify lymphoid progenitor cells (LPCs) that coexpressed hematopoietic progenitor antigens CD34, CD117, and CD133, with lymphoid differentiation markers CD21 and/or CD22 in B-cell lymphoma. " 06/01/1992 - "In systemic radioimmunotherapy, positive results have been obtained in more radiosensitive types of malignancies such as B cell lymphomas by intravenous injection of antibodies directed against B cell differentiation markers or against idiotypic antigens from each lymphoma, and labeled with 131I or 90Y. "
4.	Multiple Myeloma 07/01/2009 - "The ex vivo propagation of primary multiple myeloma cells resulted in significant increase in their differentiation markers. " 05/01/1991 - "The surface phenotype of neoplastic plasma cells from peripheral blood of plasma cell leukaemia patients and bone marrow of patients with myelomatosis was investigated with two monoclonal antibody panels including 50 selected from the B cell panel of the IVth International Workshop on Leucocyte Differentiation Antigens. " 07/01/2009 - "The incubation of multiple myeloma cells with bone marrow-derived mesenchymal stromal cells resulted in significant reduction of the expression of the predominant plasma cell differentiation markers CD38 and CD138, and cell surface immunoglobulin light chain. " 06/01/1988 - "An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens."
5.	Graft vs Host Disease (Graft-Versus-Host Disease) 04/01/1984 - "These findings (1) show for the first time in a human model that monoclonal antibodies, directed against certain differentiation antigens when linked to ricin A chain are not as effective in normal or malignant cell killing as when linked to intact ricin; (2) contribute to the growing body of evidence showing that monoclonal antibody A chain conjugates do not permit the acquisition of levels of toxin sufficient to destroy target cells; and (3) are important relative to increasing interest in use of antibody-toxin conjugates for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation."

Related Drugs and Biologics

1.	Antibodies
2.	Monoclonal Antibodies
3.	Antigens
4.	p38 Mitogen-Activated Protein Kinases
5.	Ricin
6.	Immunoglobulin Light Chains (Immunoglobulin Light Chain)
7.	Immunotoxins (Immunotoxin)
8.	roscovitine
9.	MART-1 Antigen
10.	Keratins (Keratin)

Related Therapies and Procedures

1.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
2.	Radioimmunotherapy
3.	Intravenous Injections
4.	Immunotherapy
5.	Drug Therapy (Chemotherapy)